Literature DB >> 23651022

Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records.

Matthew T Oetjens1, Joshua C Denny, Marylyn D Ritchie, Niloufar B Gillani, Danielle M Richardson, Nicole A Restrepo, Jill M Pulley, Holli H Dilks, Melissa A Basford, Erica Bowton, Dan R Masys, Russell A Wilke, Dan M Roden, Dana C Crawford.   

Abstract

BACKGROUND: The ADME Core Panel assays 184 variants across 34 pharmacogenes, many of which are difficult to accurately genotype with standard multiplexing methods.
METHODS: We genotyped 326 frequently medicated individuals of European descent in Vanderbilt's biorepository linked to de-identified electronic medical records, BioVU, on the ADME Core Panel to assess quality and performance of the assay. We compared quality control metrics and determined the extent of direct and indirect marker overlap between the ADME Core Panel and the Illumina Omni1-Quad.
RESULTS: We found the quality of the ADME Core Panel data to be high, with exceptions in select copy number variants and markers in certain genes (notably CYP2D6). Most of the common variants on the ADME panel are genotyped by the Omni1, but absent rare variants and copy number variants could not be accurately tagged by single markers.
CONCLUSION: Our frequently medicated study population did not convincingly differ in allele frequency from reference populations, suggesting that heterogeneous clinical samples (with respect to medications) have similar allele frequency distributions in pharmacogenetics genes compared with reference populations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23651022      PMCID: PMC3725600          DOI: 10.2217/pgs.13.64

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  31 in total

1.  PharmGKB: the Pharmacogenetics Knowledge Base.

Authors:  Micheal Hewett; Diane E Oliver; Daniel L Rubin; Katrina L Easton; Joshua M Stuart; Russ B Altman; Teri E Klein
Journal:  Nucleic Acids Res       Date:  2002-01-01       Impact factor: 16.971

2.  The International HapMap Project.

Authors: 
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

Review 3.  Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity.

Authors:  M Ingelman-Sundberg
Journal:  Pharmacogenomics J       Date:  2005       Impact factor: 3.550

Review 4.  Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System.

Authors:  Carmen Dumaual; Xin Miao; Thomas M Daly; Carsten Bruckner; Reuben Njau; Dong-Jing Fu; Sandra Close-Kirkwood; Nancy Bauer; Nancy Watanabe; Paul Hardenbol; Richard D Hockett
Journal:  Pharmacogenomics       Date:  2007-03       Impact factor: 2.533

5.  Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chips.

Authors:  Kaori Nakamoto; Judith R Kidd; Robert D Jenison; Curtis D Klaassen; Yu-Jui Yvonne Wan; Kenneth K Kidd; Xiao-Bo Zhong
Journal:  Pharmacogenet Genomics       Date:  2007-02       Impact factor: 2.089

6.  Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update.

Authors:  M V Relling; E E Gardner; W J Sandborn; K Schmiegelow; C-H Pui; S W Yee; C M Stein; M Carrillo; W E Evans; J K Hicks; M Schwab; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2013-01-17       Impact factor: 6.875

7.  The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

Authors:  R A Wilke; L B Ramsey; S G Johnson; W D Maxwell; H L McLeod; D Voora; R M Krauss; D M Roden; Q Feng; R M Cooper-Dehoff; L Gong; T E Klein; M Wadelius; M Niemi
Journal:  Clin Pharmacol Ther       Date:  2012-05-23       Impact factor: 6.875

Review 8.  Combinatorial pharmacogenetics.

Authors:  Russell A Wilke; David M Reif; Jason H Moore
Journal:  Nat Rev Drug Discov       Date:  2005-11       Impact factor: 84.694

Review 9.  Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants.

Authors:  David R Nelson; Darryl C Zeldin; Susan M G Hoffman; Lois J Maltais; Hester M Wain; Daniel W Nebert
Journal:  Pharmacogenetics       Date:  2004-01

10.  SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes.

Authors:  Bernice R Packer; Meredith Yeager; Laura Burdett; Robert Welch; Michael Beerman; Liqun Qi; Hugues Sicotte; Brian Staats; Mekhala Acharya; Andrew Crenshaw; Andrew Eckert; Vinita Puri; Daniela S Gerhard; Stephen J Chanock
Journal:  Nucleic Acids Res       Date:  2006-01-01       Impact factor: 16.971

View more
  15 in total

Review 1.  Emerging Role of Precision Medicine in Cardiovascular Disease.

Authors:  Jane A Leopold; Joseph Loscalzo
Journal:  Circ Res       Date:  2018-04-27       Impact factor: 17.367

2.  Elements for adequate informed consent in the surgical context.

Authors:  Hernando Abaunza; Klaus Romero
Journal:  World J Surg       Date:  2014-07       Impact factor: 3.352

3.  Minimum information required for a DMET experiment reporting.

Authors:  Judit Kumuthini; Mamana Mbiyavanga; Emile R Chimusa; Jyotishman Pathak; Panu Somervuo; Ron Hn Van Schaik; Vita Dolzan; Clint Mizzi; Kusha Kalideen; Raj S Ramesar; Milan Macek; George P Patrinos; Alessio Squassina
Journal:  Pharmacogenomics       Date:  2016-08-22       Impact factor: 2.533

4.  Evidence for extensive pleiotropy among pharmacogenes.

Authors:  Matthew T Oetjens; William S Bush; Joshua C Denny; Kelly Birdwell; Nuri Kodaman; Anurag Verma; Holli H Dilks; Sarah A Pendergrass; Marylyn D Ritchie; Dana C Crawford
Journal:  Pharmacogenomics       Date:  2016-06-01       Impact factor: 2.533

Review 5.  Pharmacogenomics in the clinic.

Authors:  Mary V Relling; William E Evans
Journal:  Nature       Date:  2015-10-15       Impact factor: 49.962

Review 6.  Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.

Authors:  Henry M Dunnenberger; Kristine R Crews; James M Hoffman; Kelly E Caudle; Ulrich Broeckel; Scott C Howard; Robert J Hunkler; Teri E Klein; William E Evans; Mary V Relling
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-02       Impact factor: 13.820

Review 7.  Implementation of inpatient models of pharmacogenetics programs.

Authors:  Larisa H Cavallari; Craig R Lee; Julio D Duarte; Edith A Nutescu; Kristin W Weitzel; George A Stouffer; Julie A Johnson
Journal:  Am J Health Syst Pharm       Date:  2016-12-01       Impact factor: 2.637

8.  Utilization of an EMR-biorepository to identify the genetic predictors of calcineurin-inhibitor toxicity in heart transplant recipients.

Authors:  Matthew Oetjens; William S Bush; Kelly A Birdwell; Holli H Dilks; Erica A Bowton; Joshua C Denny; Russell A Wilke; Dan M Roden; Dana C Crawford
Journal:  Pac Symp Biocomput       Date:  2014

9.  THE CHALLENGES IN USING ELECTRONIC HEALTH RECORDS FOR PHARMACOGENOMICS AND PRECISION MEDICINE RESEARCH.

Authors:  Sarah M Laper; Nicole A Restrepo; Dana C Crawford
Journal:  Pac Symp Biocomput       Date:  2016

10.  The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients.

Authors:  Doreen Z Mhandire; Andrew K L Goey
Journal:  Mol Diagn Ther       Date:  2022-02-03       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.